Jim Geraghty is an industry leader with 30 years of strategic leadership experience, including more than 20 years developing and commercialization therapies for rare diseases. Mr. Geraghty most recently served as an entrepreneur-in-residence at Third Rock Ventures, focused on creating companies dedicated to improving the lives of patients with rare genetic diseases. Prior to joining Third Rock in 2013, Mr. Geraghty served as Senior Vice President, North America Strategy and Business Development at Sanofi. Before Sanofi, Mr. Geraghty spent 20 years at Genzyme, as Senior Vice President and an Executive Officer, President of Genzyme Europe, and General Manager of Genzyme’s cardiovascular business. He also served as chairman and CEO of GTC Biotherapeutics (originally Genzyme Transgenics). He is chairman of Idera Pharmaceuticals and of Juniper Pharmaceuticals, and serves on the board of directors of Fulcrum Therapeutics and of BIO Ventures for Global Health. A graduate of the Yale Law School, Mr. Geraghty holds a Masters of Science from the University of Pennsylvania and a Bachelors of Art from Georgetown University.